A double-blind, randomized, placebo-controlled trial conducted to
evaluate the efficacy and safety of a 3-day course of remdesivir in
high-risk, non-hospitalized patients with COVID-19.
About the Podcast
We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.